Scholarlink

Background <p>Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is associated with increased malignancy risk. This study assessed national trends in malignancy-related mortality among United States IBD patients from 1999 to 2020 using representative data.</p> Methods <p>A retrospective, population-based analysis was conducted using the Centers for Disease Control and Prevention (CDC) Wide-ranging Online Data for Epidemiologic Research (WONDER) database. Deaths among individuals with IBD were identified using ICD-10 codes K50 and K51, while malignancy-related deaths were captured using codes C00–C97. Crude and Age-adjusted mortality rates (AMRs) were calculated and stratified by sex, ethnicity, region, state, and age group. Linear regression models evaluated trends and forecast malignancy-related mortality through 2030.</p> Results <p>Between 1999 and 2020, 9,531 malignancy-related deaths occurred among IBD patients. Malignancy-related deaths rose significantly, increasing by 108.3% (p = 0.010, R<sup>2</sup> = 0.439). Higher AMRs were observed among males (p = 0.009), White individuals (p = 0.019), Midwest residents (p = 0.015), and patients aged ≥ 65. The largest relative increases were among females (55.2%), White individuals (55.1%), West residents (75.2%), and those aged 65–74 years (72.6%). Lung and colon cancers were the leading causes of malignancy-related deaths. Projections suggest continued rises in malignancy-related AMRs, particularly among CD patients, while UC patients remain relatively stable.</p> Conclusion <p>Malignancy is an increasingly important contributor to mortality among US IBD patients, particularly older adults, males, Midwest residents and White individuals. These findings highlight the need for enhanced cancer surveillance, equitable healthcare access, and integrated long-term management of IBD populations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Malignancy as a rising contributor to mortality in patients with inflammatory bowel disease: a population-based epidemiological study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月26日

查看全文
  • Amr Ahmed Aly Ibrahim,
  • Mahmoud Shaaban Abdelgalil,
  • Sara Hosny El-Farargy,
  • Rahma Sameh Shaheen,
  • Moaz Yasser Darwish,
  • Ahmad Abdelrazek,
  • Sara Metwally,
  • Mohamed Adel Nassef,
  • Karim Samir Attia,
  • Mohamed Abd-ElGawad

摘要

Background

Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is associated with increased malignancy risk. This study assessed national trends in malignancy-related mortality among United States IBD patients from 1999 to 2020 using representative data.

Methods

A retrospective, population-based analysis was conducted using the Centers for Disease Control and Prevention (CDC) Wide-ranging Online Data for Epidemiologic Research (WONDER) database. Deaths among individuals with IBD were identified using ICD-10 codes K50 and K51, while malignancy-related deaths were captured using codes C00–C97. Crude and Age-adjusted mortality rates (AMRs) were calculated and stratified by sex, ethnicity, region, state, and age group. Linear regression models evaluated trends and forecast malignancy-related mortality through 2030.

Results

Between 1999 and 2020, 9,531 malignancy-related deaths occurred among IBD patients. Malignancy-related deaths rose significantly, increasing by 108.3% (p = 0.010, R2 = 0.439). Higher AMRs were observed among males (p = 0.009), White individuals (p = 0.019), Midwest residents (p = 0.015), and patients aged ≥ 65. The largest relative increases were among females (55.2%), White individuals (55.1%), West residents (75.2%), and those aged 65–74 years (72.6%). Lung and colon cancers were the leading causes of malignancy-related deaths. Projections suggest continued rises in malignancy-related AMRs, particularly among CD patients, while UC patients remain relatively stable.

Conclusion

Malignancy is an increasingly important contributor to mortality among US IBD patients, particularly older adults, males, Midwest residents and White individuals. These findings highlight the need for enhanced cancer surveillance, equitable healthcare access, and integrated long-term management of IBD populations.